189.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$192.50
Aprire:
$192.64
Volume 24 ore:
1.43M
Relative Volume:
0.28
Capitalizzazione di mercato:
$294.50B
Reddito:
$58.80B
Utile/perdita netta:
$10.24B
Rapporto P/E:
57.92
EPS:
3.2788
Flusso di cassa netto:
$8.98B
1 W Prestazione:
-2.22%
1M Prestazione:
-7.61%
6M Prestazione:
+138.69%
1 anno Prestazione:
+148.20%
Astrazeneca Plc Stock (AZN) Company Profile
Nome
Astrazeneca Plc
Settore
Industria
Telefono
-
Indirizzo
-
Compare AZN vs LLY, JNJ, ABBV, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2025-10-27 | Ripresa | Jefferies | Buy |
| 2025-10-16 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca Plc Borsa (AZN) Ultime notizie
Could This International ETF Be One of the Best Investments of 2026? - The Motley Fool
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - AOL.com
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance Singapore
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
AstraZeneca (LSE:AZN) Valuation Insights After Recent Price Moves - Kalkine Media
AZN Stock Price and Chart — LSE:AZN - TradingView
AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals - TipRanks
AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy - TipRanks
AstraZeneca (AZN) Refutes Takeover Speculation - GuruFocus
$100 Million AstraZeneca Deal Puts Chinese Biotech Jacobio on Path to Profit - Caixin Global
Abivax denies AstraZeneca takeover rumors reported by French media - Reuters
Abivax Denies La Lettre Report of AstraZeneca Exclusivity - marketscreener.com
Abivax Denies La Lettre Report of AstraZeneca Exclusivity, Bloomberg Reports - marketscreener.com
Van ECK Associates Corp Sells 72,809 Shares of AstraZeneca PLC $AZN - MarketBeat
SageView Advisory Group LLC Acquires New Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Sha - GuruFocus
BNP Paribas Financial Markets Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
Capital Research Global Investors Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca in pole position to acquire Abivax - marketscreener.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
Morgan Stanley Sees Double-Digit EPS Growth for AstraZeneca PLC (AZN) - Insider Monkey
Franklin Resources Inc. Sells 1,585,664 Shares of AstraZeneca PLC $AZN - MarketBeat
Russell Investments Group Ltd. Has $66.19 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Position Boosted by Bank of Montreal Can - MarketBeat
In Brief: Jacobio/AZ’s JAB-23E73 Reports First Clinical Results For Pan-KRAS Inhibitors - Citeline News & Insights
AZN Stock Price, Quote & Chart | ASTRAZENECA PLC-SPONS ADR (NYSE:AZN) - ChartMill
Zoladex Market Is Booming Worldwide 2026-2033 | AstraZeneca, Pfizer, Ipsen, Novartis - openPR.com
AstraZeneca awards $3.4 million to US nonprofits to expand healthcare access - MSN
AstraZeneca schedules digital annual general meeting for April 9 - Investing.com South Africa
Joshua Jackson, Gritty urge fans to get checked for cancer early - Stock Titan
AstraZeneca schedules AGM for April 9, 2026 - Investing.com India
Causeway Capital Management LLC Raises Stock Position in AstraZeneca PLC $AZN - MarketBeat
Capital International Investors Sells 6,352,463 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Capital Group Private Client Services Inc. - MarketBeat
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
Capital International Inc. CA Buys 18,059 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca's Stock Ranks 395th in Trading Activity Amid Institutional Splits and 156% Dividend Yield - Bitget
First Trust Advisors LP Sells 103,714 Shares of AstraZeneca PLC $AZN - MarketBeat
Cresset Asset Management LLC Lowers Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu - marketscreener.com
AstraZeneca PLC $AZN Shares Sold by Victory Capital Management Inc. - MarketBeat
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment - GuruFocus
AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer - marketscreener.com
Brokers Offer Predictions for AstraZeneca FY2026 Earnings - MarketBeat
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns - GuruFocus
Natixis Advisors LLC Buys 262,465 Shares of AstraZeneca PLC $AZN - MarketBeat
Legacy Capital Group California Inc. Buys New Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Purchased by Guardian Capital LP - MarketBeat
AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value - TipRanks
AstraZeneca executives receive vested shares under deferred bonus plan - Investing.com India
AstraZeneca CEO Pascal Soriot receives vested shares under performance plan - Investing.com UK
Astrazeneca Plc Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):